Ascendis Pharma A/S (NASDAQ:ASND) Price Target Lowered to $180.00 at Oppenheimer

Ascendis Pharma A/S (NASDAQ:ASND) had its target price dropped by research analysts at Oppenheimer from $190.00 to $180.00 in a research note issued on Friday,Benzinga reports. The firm presently has an “outperform” rating on the biotechnology company’s stock. Oppenheimer’s target price indicates a potential upside of 41.58% from the company’s current price.

ASND has been the topic of a number of other research reports. TD Cowen increased their price target on shares of Ascendis Pharma A/S from $157.00 to $160.00 and gave the stock a “buy” rating in a report on Monday, October 21st. Wells Fargo & Company increased their price target on shares of Ascendis Pharma A/S from $264.00 to $289.00 and gave the stock an “overweight” rating in a report on Tuesday, September 17th. StockNews.com lowered shares of Ascendis Pharma A/S from a “hold” rating to a “sell” rating in a report on Tuesday. The Goldman Sachs Group increased their price target on shares of Ascendis Pharma A/S from $180.00 to $200.00 and gave the stock a “buy” rating in a report on Tuesday, September 17th. Finally, JPMorgan Chase & Co. decreased their price target on shares of Ascendis Pharma A/S from $180.00 to $174.00 and set an “overweight” rating on the stock in a report on Wednesday, October 23rd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and twelve have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Ascendis Pharma A/S currently has an average rating of “Moderate Buy” and a consensus target price of $192.31.

Ascendis Pharma A/S Stock Performance

NASDAQ ASND traded up $2.86 on Friday, hitting $127.14. The stock had a trading volume of 435,994 shares, compared to its average volume of 445,568. Ascendis Pharma A/S has a 52-week low of $90.13 and a 52-week high of $161.00. The company has a market capitalization of $7.71 billion, a price-to-earnings ratio of -13.72 and a beta of 0.66. The firm has a 50-day moving average of $132.15 and a 200-day moving average of $132.80.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The business had revenue of $38.75 million for the quarter, compared to analyst estimates of $94.74 million. As a group, research analysts anticipate that Ascendis Pharma A/S will post -7.35 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD boosted its position in shares of Ascendis Pharma A/S by 23.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company’s stock valued at $269,374,000 after buying an additional 336,976 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in Ascendis Pharma A/S by 63.8% during the third quarter. China Universal Asset Management Co. Ltd. now owns 11,142 shares of the biotechnology company’s stock valued at $1,664,000 after buying an additional 4,338 shares during the last quarter. Evolutionary Tree Capital Management LLC grew its stake in shares of Ascendis Pharma A/S by 82.3% in the 2nd quarter. Evolutionary Tree Capital Management LLC now owns 24,862 shares of the biotechnology company’s stock worth $3,391,000 after buying an additional 11,223 shares in the last quarter. SG Americas Securities LLC increased its position in shares of Ascendis Pharma A/S by 221.0% during the 2nd quarter. SG Americas Securities LLC now owns 6,108 shares of the biotechnology company’s stock valued at $833,000 after purchasing an additional 4,205 shares during the last quarter. Finally, Acadian Asset Management LLC boosted its position in shares of Ascendis Pharma A/S by 1,461.1% during the first quarter. Acadian Asset Management LLC now owns 250,492 shares of the biotechnology company’s stock valued at $37,849,000 after buying an additional 234,446 shares during the period.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.